XTLB

XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) is an Israeli biopharmaceutical company founded in 1993 and headquartered in Ramat Gan, Israel. Originally incorporated as Xenograft Technologies Ltd., the company changed its name to XTL Biopharmaceuticals in July 1995 and went public in September 2005. XTL operates as a clinical-stage biotechnology company focused on acquiring and developing pharmaceutical treatments for autoimmune diseases, with its primary asset being a Phase II-ready drug candidate for treating systemic lupus erythematosus and Sjögren's syndrome.